Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III trial of V260 in healthy Japanese infants
2017-000264-15Phase 3
- Sponsor
- Merck & Co.
- Start
- Mar 2017
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised trial in rotaviral diarrhea comparing V260 with Placebo (2 arms). Primary endpoint: Incidence rate of rotavirus gastroenteritis caused by target serotypes.
02
Drugs
rotavirus vaccine, live, oral, pentavalent
03
Conditions
rotaviral diarrhea
Beyond the preview
Go deeper on 2017-000264-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-000264-15.